Sharp Therapeutics Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Apr '26 Apr 16, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Capitalization	63	75	30	-	-
Market Cap Growth	-	153.22%	-	-	-
Enterprise Value	64	74	50	-	-
Last Close Price	2.10	2.50	1.05	1.05	-
PB Ratio	-260.84	-309.88	7.97	-	-
P/TBV Ratio	-	-	7.97	-	-
Debt / Equity Ratio	-7.26	-7.26	0.51	-1.10	-1.15
Net Debt / Equity Ratio	-1.85	-1.85	-0.84	-1.06	-1.13
Net Debt / EBITDA Ratio	-0.06	-0.06	0.86	-5.46	-3.78
Net Debt / FCF Ratio	-0.07	-0.07	0.60	-6.20	-4.36
Quick Ratio	1.00	1.00	5.05	0.05	0.04
Current Ratio	1.06	1.06	5.10	0.06	0.05
Return on Equity (ROE)	-512.77%	-512.77%	-	-	-
Return on Assets (ROA)	-105.91%	-105.91%	-52.06%	-95.55%	-
Return on Capital Employed (ROCE)	-552.80%	-552.80%	-65.80%	36.70%	86.80%
Earnings Yield	-13.40%	-11.28%	-15.83%	-	-
FCF Yield	-	-8.83%	-17.63%	-	-
Buyback Yield / Dilution	-227.37%	-227.37%	-107.12%	-3028.62%	-

Source: S&P Capital IQ. Standard template. Financial Sources.